Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Foundation Medicine and Memorial Sloan-Kettering Cancer Center Announce Partnership

Published: Friday, May 03, 2013
Last Updated: Friday, May 03, 2013
Bookmark and Share
Partners will co-develop a genomic test to help guide treatment decisions for patients diagnosed with leukemia, lymphoma or myeloma.

Foundation Medicine and Memorial Sloan-Kettering Cancer Center have announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.

This effort will focus on co-development of a new Foundation Medicine molecular diagnostic product designed to match patients with hematologic cancers (leukemia, lymphoma or myeloma) with the most rational targeted therapies or clinical trials for their cancer.

Leaders in hematology from Memorial Sloan-Kettering will help accelerate product development by providing clinical and genomic expertise.

This product complements FoundationOne™, Foundation Medicine’s first product, which offers a similar fully informative genomic profile for solid tumors and likewise provides a concise report to assist physicians in matching patients with the targeted drugs or clinical trials best suited for their unique cancer. FoundationOne was launched in 2012.

“The development of clinical grade sequencing is rapidly changing the practice of oncology, enabling us to more precisely understand and target the genomic alterations that drive a patient’s individual cancer,” said Craig B. Thompson, M.D., president and chief executive officer of Memorial Sloan-Kettering Cancer Center.

Thompson continued, “We are partnering with Foundation Medicine to develop a best-in-class assay for hematologic cancers because we view achieving this goal as an extension of our mission as a comprehensive cancer center: making it possible for all patients to be treated with the therapy that is matched with their individual cancer.”

“Memorial Sloan-Kettering is one of the world’s premier cancer centers with deep scientific and clinical understanding of hematologic cancers and a commitment to driving a new genomic paradigm of individualized cancer care,” said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine.

Pellini continued, “Our approach is to collaborate with leaders like Memorial Sloan-Kettering across all areas of clinical oncology and cancer genomics and seek partners who are equally committed to the changing paradigm of cancer care. This is the ideal partnership to support the development of our new product for patients with hematologic malignancies.”

This new test is being developed using RNA sequencing in addition to DNA sequencing to better enable identification of the unique genes and classes of genomic alterations that are characteristic of hematologic malignancies.

Similar to FoundationOne, the new hematologic malignancy test will assist physicians by matching these alterations with targeted treatment options that may be relevant to the patient’s genomic profile based on a comprehensive review of published literature.

The test will be based on technology, methods and computational algorithms developed by Foundation Medicine, and Foundation Medicine will commercialize the test both in the United States and internationally.

Memorial Sloan-Kettering will help accelerate the development and optimization of the product by contributing their clinical and genomic expertise in hematologic malignancies.

Foundation Medicine operates a CLIA-certified lab in Cambridge, Mass. and receives clinical patient samples from academic medical centers and community hospitals all over the world. The new test is expected to be commercially available by year-end 2013.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Foundation Medicine’s Next-Generation Sequencing Data to be Presented at 103rd AACR Annual Meeting 2012
Genomic profile demonstrates high concordance with existing commercial assays and identifies broader range of actionable alterations.
Wednesday, March 28, 2012
Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer
Findings highlight clinical application of next-generation sequencing to suggest targeted therapeutic options for patients.
Tuesday, February 14, 2012
Foundation Medicine Receives CLIA Certification for Its Genomic Sequencing Laboratory
This certification follows receipt of a Massachusetts State license and allows the company to accept clinical samples from most U.S. states.
Friday, February 03, 2012
Scientific News
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
‘Poring Over’ DNA
Advancing nanopore sensing towards lower cost and more accurate DNA sequencing.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Know your Enemy
Genetic markers for mosquitos which prefer humans to cattle identified for improved malaria surveillance and control.
NASA's DNA Sequencing in Space is a Success
DNA has been sequenced in space for the first time ever for the Biomolecule Sequencer investigation, using the MinION sequencing device.
New Inflammatory Disease Discovered
NIH researchers have discovered a rare and potentially deadly disease - otulipenia - the mostly affects children.
Bringing NGS to the Crime Lab
New technology being validated in BCI lab for use in Ohio missing persons cases.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos